From the Desk of Kimmy Sokoloff

Yesterday was a one-hit wonder for longs. Today was pretty ugly.

The market is showing who's in charge.

The $SPX broke through support levels at 3,850 and 3,800. Next support is at 3,744.

From the Desk of Kimmy Sokoloff

Futures down some after yesterday's nice move to the upside.

It could be a consolidation day, but I would like $SPX 3,850 held today. 

The largest insider transaction on today’s list came in a Form 4 filing from Durable Capital Partners.

The hedge fund reported an additional purchase of $8.7 million in Duolingo $DUOL.

I don't know how many times I've said it this year. Someone go back and count.

But the catalyst IS THE WEAKER DOLLAR.

It's not the fed, or the election, or yield curves, or wars, or Santa Claus or any of the other random arguments that we've all heard along the way.

It's the US Dollar.

Period.

From the desk of Steve Strazza @Sstrazza

Welcome to the 2 to 100 Club.

As many of you know, something we've been working on internally is using various bottom-up tools and scans to complement our top-down approach. It's really been working for us!

One way we're doing this is by identifying the strongest growth stocks as they climb the market-cap ladder from small- to mid- to large- and, ultimately, to mega-cap status (over $200B).

Once they graduate from small-cap to mid-cap status (over $2B), they come on our radar. Likewise, when they surpass the roughly $30B mark, they roll off our list.

But the scan doesn't just end there.

We only want to look at the strongest growth industries in the market, as that is typically where these potential 50-baggers come from.

Some of the best performers in recent decades – stocks like Priceline, Amazon, Netflix, Salesforce, and myriad others – would have been on this list at some point during their...

From the Desk of Kimmy Sokoloff

In today's Morning Briefing, I wrote about $SPY and $TQQQ trade ideas.

Both targets were reached. SPY ran right into resistance at 387 and then pulled back, as was alerted.

This is the video recording of our December 21, 2022, Inside Scoop Weekly Strategy Session.

Senator Tommy Tuberville of Alabama is back on our list after filing his first Periodic Transaction Report since early November.

Here’s what Sen. Tuberville is buying:

• Intel Corporation $INTC ($100,000 - $250,000)
• Activision Blizzard $ATVI ($100,000 - $250,000)
• Cleveland-Cliffs $CLF ($50,000 - $100,000)

While Activision is a new name for Tuberville, these are the second purchases he has made in both Intel and Cleveland-Cliffs in recent months.

From the Desk of Kimmy Sokoloff

As I write this note, the futures are gapping higher.

The cash index could open roughly at $SPX 3,850 -- that is, as long as we stay higher.

Thanks to everyone who joined us live last night on our Mid-month Conference Call.

We had a lot to talk about.

There are plenty of opportunities out there to profit. These are exciting times for sure.

One of the charts I discussed was the performance of different types of stocks since the market bottomed in June.

Here's each sector's performance since June 16th, which was the day that the NYSE new lows list peaked:

This is the video recording of the December 2022 Mid-month Conference Call.

We discussed:

• The S&P500 & DJ Industrial Avg below overhead supply
• Median Stock is above Key Long-term Support
• Consumer Staples & Low Volatility Stocks outperforming
• Performance of Sectors since Stocks Bottomed June 16th
• Waiting for an expansion of the new highs list
• The implications of a stronger Japanese Yen
• Dollar weakening vs Developed Market & Emerging Market Currencies
• 4-year Presidential Cycle Bullish Sweet Spot
• Small-caps to buy that are outperforming
• Bonds making new highs
• Interest rates impact on Growth Stocks
• Which Energy Stocks To Buy Now
• The relentless bid in Gold & Precious Metals
• Which Gold & Silver stocks to own
• Sugar and Soybeans breaking out
• Copper Underperforming Gold
• Chinese Stocks leading the way
• European Financials outperforming U.S. Financials
• Industrials Leading - which ones to buy
• Mega-cap Healthcare as a defensive trade
• ...